胃外科实验研究的现状与展望

Present status and prospect of experimental study on gastric surgery

胃癌是我国最常见的恶性肿瘤之一,大约80%的患者在就诊时已经处于进展期,治疗效果有限,总体预后不佳。寻找新的治疗方法,改进已有的治疗措施是目前亟待解决的关键问题。随着临床研究结果的逐渐发布,以纳武单抗(Nivolumab)和派姆单抗(Pembrolizumab)为代表的免疫检查点抑制剂为晚期胃癌患者的治疗提供了新的选择,同时精准的分子分型和规范的外科手术也开启了胃癌个体化治疗的新篇章。以外科手术、化疗和免疫治疗为基础的综合治疗将在一定程度上改善部分胃癌患者的预后。

Gastric cancer is one of the most common malignant tumors in our country, and about 80% of patients are already in an advanced stage at the time of diagnosis. The treatment options have limited therapeutic benefit and the overall prognosis is poor. Finding new therapies and improving existing measures are the vital problems to be solved currently. The immune checkpoint inhibitors provide a new choice for the treatment of patients with advanced gastric cancer. The molecular classification and standardized surgical technique also start a new chapter in the individual treatment of this disease. Comprehensive treatment based on surgery, chemotherapy, and immunotherapy will improve the prognosis of selected patients with advanced gastric cancer to some extent.